Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865237 | 0.89 | LMNA (0.65) | ALDH1A1CYP3A4LMNACASP6TSHR | |
| SCHEMBL4632273 | 0.84 | LMNA (0.64) | ALDH1A1LMNACASP6TSHRTPMT | |
| SCHEMBL10756347 | 0.84 | CASP6 (0.55) | ALDH1A1LMNACASP6TSHRTPMT | |
| SCHEMBL8841185 | 0.83 | CASP6 (0.62) | ALDH1A1LMNACASP6TSHRTPMT | |
| SCHEMBL9706244 | 0.82 | TTR (0.62) | ALDH1A1LMNACASP6TSHRTPMT | |
| SCHEMBL2895332 | 0.82 | CASP6 (0.53) | ALDH1A1LMNACASP6TSHRTPMT | |
| SCHEMBL2894998 | 0.81 | TSHR (0.56) | ALDH1A1LMNACASP6TSHRTPMT | |
| SCHEMBL1509549 | 0.81 | TSHR (0.60) | ALDH1A1CYP3A4LMNACASP6TSHR | |
| SCHEMBL3708951 | 0.81 | LMNA (0.56) | ALDH1A1LMNACASP6TSHRTPMT | |
| SCHEMBL12479698 | 0.81 | CASP6 (0.51) | ALDH1A1LMNACASP6TSHRTPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805317-A | Preparation method of Tegolrazan | 江苏威奇达药业有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-117511246-A | Dispersing agent for high-temperature direct-injection blue disperse dye ink and application of dispersing agent in high-temperature direct-injection blue disperse dye ink | 沈阳化工研究院有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-114805317-A | Preparation method of Tegolrazan | 江苏威奇达药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| EP-2410857-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011099832-A2 | NOVEL BENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CRYSTALGENOMICS, INC. (KR) | 2011-08-18 | — | — | WO | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2003053439-A1 | USE OF BENZOFUROXAN DERIVATIVES AS ANTIPLATELET AGENTS | SANKARANARAYANAN ALANGUDI (IN) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | ALDH1A1 2538/4885CYP3A4 4166/4885LMNA 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.